AR063467A1 - PREPARATION OF PHARMACEUTICAL SALTS OF ACID 3-O- (3 ', 3'-DIMETILSUCCINIL) BETULINICO; SALTS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THESE IN THE TREATMENT OF HIV INFECTIONS. - Google Patents

PREPARATION OF PHARMACEUTICAL SALTS OF ACID 3-O- (3 ', 3'-DIMETILSUCCINIL) BETULINICO; SALTS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THESE IN THE TREATMENT OF HIV INFECTIONS.

Info

Publication number
AR063467A1
AR063467A1 ARP060105575A ARP060105575A AR063467A1 AR 063467 A1 AR063467 A1 AR 063467A1 AR P060105575 A ARP060105575 A AR P060105575A AR P060105575 A ARP060105575 A AR P060105575A AR 063467 A1 AR063467 A1 AR 063467A1
Authority
AR
Argentina
Prior art keywords
betulinic acid
dimethylsuccinyl
salts
salt
acid
Prior art date
Application number
ARP060105575A
Other languages
Spanish (es)
Original Assignee
Hemp Christian
Theodore John
Swaringen Jr Roy A
Hausherr Arndt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemp Christian, Theodore John, Swaringen Jr Roy A, Hausherr Arndt filed Critical Hemp Christian
Publication of AR063467A1 publication Critical patent/AR063467A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un proceso para preparar ácido 3-O-(3',3'-dimetilsuccinil)betulínico, (ôDSBö). También se refiere a su uso para tratar el VIH y enfermedades relacionadas mediante composiciones farmacéuticas que comprenden formas salinas del DSB preparadas de acuerdo con el proceso de la presente. También se refiere a formas de dosificacion de composiciones farmacéuticas que comprenden sales del DSB preparadas utilizando el proceso de la presente. Reivindicacion 1: Un proceso para preparar en forma regioselectiva ácido 3-O-(3',3'-dimetilsuccinil)betulínico con un rendimiento mayor que el ácido 3-O-(2',2'-dimetilsuccinil)betulínico que comprende hacer reaccionar anhídrido 2,2-dimetilsuccínico con ácido betulínico en presencia de una base adecuada. Reivindicacion 5: Un proceso para preparar el ácido 3-O-(3',3'-dimetilsuccinil)betulínico, que comprende proporcionar un compuesto de Formula 2, donde Mn+ es un cation con estado de oxidacion n y n es 1 o 2; Formula 3 donde Mk+ es un cation con estado de oxidacion k; cada uno de k y m es 1 o 2 con la condicion de que cuando m = 1, k = 2 y cuando m = 2, k = 1; o Formula 4 donde cada uno de Mk+ y Qn+ es independientemente un mono- o un di-cation, cada uno de k y n es independientemente 1 o 2, cada uno de a y b es de 0 a 2, y c es 1 o 2, con la condicion de que la electroneutralidad de la sal no sea violada; y convertir dicho compuesto al ácido 3-O-(3',3'-dimetilsuccinil)betulínico. Reivindicacion 27: Un proceso para preparar ácido 3-O-(3',3'-dimetilsuccinil)betulínico que comprende: (a) hacer reaccionar una sal del ácido betulínico con anhídrido 2,2-dimetilsuccínico en un solvente adecuado y (b)recuperar el producto. Reivindicacion 47: Ácido 3-O- (3',3'-dimetilsuccinil)betulínico que tiene por lo menos 85% de pureza regioisomérica con respecto al ácido 3-O-(2',2'-dimetilsuccinil)betulínico preparado por un proceso que consiste esencialmente en: (a) hacer reaccionar una sal de ácido betulínico con anhídrido 2,2-dimetilsuccínico en un solvente adecuado; y (b) recuperar el producto. Reivindicacion 48: Ácido 3-O-(3',3'-dimetilsuccinil)betulínico que tiene por lo menos 90% de pureza regioisomérica con respecto al ácido 3-O-(2',2'- dimetilsuccinil)betulínico preparado por un proceso que consiste en esencialmente en: (a) hacer reaccionar una sal de ácido betulínico con anhídrido 2,2-dimetilsuccínico en un solvente adecuado; y (b) recuperar el producto.A process for preparing 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid, (ôDSBö). It also refers to its use to treat HIV and related diseases by pharmaceutical compositions comprising salt forms of DSB prepared in accordance with the process herein. It also refers to dosage forms of pharmaceutical compositions comprising DSB salts prepared using the process herein. Claim 1: A process for preparing regioselectively 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid with a yield greater than 3-O- (2', 2'-dimethylsuccinyl) betulinic acid comprising reacting 2,2-dimethyl succinic anhydride with betulinic acid in the presence of a suitable base. Claim 5: A process for preparing 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid, comprising providing a compound of Formula 2, wherein Mn + is a cation with oxidation state n and n is 1 or 2; Formula 3 where Mk + is a cation with oxidation state k; each of k and m is 1 or 2 with the proviso that when m = 1, k = 2 and when m = 2, k = 1; or Formula 4 where each of Mk + and Qn + is independently a mono- or di-cation, each of kyn is independently 1 or 2, each of a and b is from 0 to 2, and c is 1 or 2, with the condition that the electroneutrality of the salt is not violated; and converting said compound to 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid. Claim 27: A process for preparing 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid comprising: (a) reacting a salt of betulinic acid with 2,2-dimethyl succinic anhydride in a suitable solvent and (b) Recover the product. Claim 47: 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid having at least 85% regioisomeric purity with respect to 3-O- (2', 2'-dimethylsuccinyl) betulinic acid prepared by a process consisting essentially of: (a) reacting a salt of betulinic acid with 2,2-dimethyl succinic anhydride in a suitable solvent; and (b) recover the product. Claim 48: 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid having at least 90% regioisomeric purity with respect to 3-O- (2', 2'-dimethylsuccinyl) betulinic acid prepared by a process consisting essentially of: (a) reacting a salt of betulinic acid with 2,2-dimethyl succinic anhydride in a suitable solvent; and (b) recover the product.

ARP060105575A 2005-12-16 2006-12-18 PREPARATION OF PHARMACEUTICAL SALTS OF ACID 3-O- (3 ', 3'-DIMETILSUCCINIL) BETULINICO; SALTS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THESE IN THE TREATMENT OF HIV INFECTIONS. AR063467A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75080505P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
AR063467A1 true AR063467A1 (en) 2009-01-28

Family

ID=38228757

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105575A AR063467A1 (en) 2005-12-16 2006-12-18 PREPARATION OF PHARMACEUTICAL SALTS OF ACID 3-O- (3 ', 3'-DIMETILSUCCINIL) BETULINICO; SALTS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THESE IN THE TREATMENT OF HIV INFECTIONS.

Country Status (11)

Country Link
US (2) US20070203103A1 (en)
EP (1) EP1968606A4 (en)
CN (1) CN101374527A (en)
AR (1) AR063467A1 (en)
AU (1) AU2006333084A1 (en)
BR (1) BRPI0619936A2 (en)
CA (1) CA2633402A1 (en)
IL (1) IL192190A0 (en)
TW (1) TW200745155A (en)
WO (1) WO2007078848A2 (en)
ZA (1) ZA200805703B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610668A2 (en) * 2005-04-12 2010-07-13 Panacos Pharmaceuticals Inc 3-o- (3 ', 3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine polymorphs
AR063546A1 (en) 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc TRITERPEN DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF INFECTION WITH HIV VIRUS.
EP2567965B1 (en) * 2011-09-12 2015-09-02 Centre National de la Recherche Scientifique (CNRS) Derivatives of 3-O-(3',3'-dimethylsuccinyl)-betulinic acid
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
CN111417384A (en) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 Methods and improved neuroprotective compositions for treating neurological conditions
PL237998B1 (en) 2018-05-28 2021-06-28 Narodowy Inst Lekow Phosphonic derivatives of 3-carboxyacylbetulinic acid, method for obtaining them and their application
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
WO2021201903A1 (en) 2020-03-31 2021-10-07 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869535A (en) * 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US6569842B2 (en) * 2000-08-18 2003-05-27 Board Of Trustees Of The University Of Illinois, The Method of preparing and use of prodrugs of betulinic acid derivatives
TW494542B (en) * 2000-12-05 2002-07-11 Winbond Electronics Corp Fabrication method of split-gate flash memory
WO2002091858A1 (en) * 2001-05-11 2002-11-21 University Of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
US7531662B2 (en) * 2003-06-11 2009-05-12 Brandeis University Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them
US20050239748A1 (en) * 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid

Also Published As

Publication number Publication date
TW200745155A (en) 2007-12-16
AU2006333084A1 (en) 2007-07-12
CN101374527A (en) 2009-02-25
EP1968606A2 (en) 2008-09-17
EP1968606A4 (en) 2009-09-16
WO2007078848A2 (en) 2007-07-12
US20070203103A1 (en) 2007-08-30
WO2007078848A3 (en) 2008-05-29
BRPI0619936A2 (en) 2011-10-25
CA2633402A1 (en) 2007-07-12
IL192190A0 (en) 2008-12-29
US20110313191A1 (en) 2011-12-22
ZA200805703B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
AR063467A1 (en) PREPARATION OF PHARMACEUTICAL SALTS OF ACID 3-O- (3 ', 3'-DIMETILSUCCINIL) BETULINICO; SALTS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THESE IN THE TREATMENT OF HIV INFECTIONS.
NI201900041A (en) 1, 2, 4-TRIAZOLONES 2, 4, 5-TRISUSTITUIDAS
CR20180307A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
AR056055A1 (en) CRYSTALLINE AND HYDRATIC COMPLEXES OF 1-CHLORINE-4- (BETA-D-GLUCOPIRANOS-1-IL) -2- (4-ETINIL-BENCIL) -BENZENE
NI201800051A (en) IMIDAZO [4, 5-C] QUINOLIN-2-ONA COMPOUNDS AND ITS USE IN THE TREATMENT OF CANCER
UY33600A (en) CARBA-NUCLEOSID ANALOGS 2` - FLUOR SUBSTITUTED FOR ANTIVIRAL TREATMENT AND USE OF THE SAME IN THE PREPARATION OF MEDICINES
BR112015020772A2 (en) pyrimidine and pyridine compounds and their use
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
ECSP109982A (en) PREPARATION PROCESS OF THE WATER SOLUBLE COMPLEX CONTAINING THE RESVERATROL COMPOUND, PRODUCTS FORMING SUCH COMPLEX AND USES OF THE SAME
BR112015018491A2 (en) c-19-modified triterpenoids with hiv maturation inhibitory activity
BR112017018643A2 (en) "Useful bicyclic tetrahydrothiazepine derivatives, pharmaceutical composition comprising them, their use, and in vitro or ex vivo method for producing activated immune cells"
AR102915A1 (en) PROCESS OF PRODUCTION OF CRYSTALS OF DIAZABICICLOOCTAN DERIVATIVE AND STABLE LIOPHILIZED PREPARATION
AR088963A1 (en) COMPLEX OBTAINED FROM Hyaluronic Acid MIXTURES OR A SALT OF THE SAME AND CONDROITINE SULFATE
CL2019002677A1 (en) Adhesive composition and method of preparing it.
BR112014003063A2 (en) "Antibacterial cyclopenta [c] pyrrol substituted 3,4-dihydro-1h- [1,8] naphthyridinones, pharmaceutical composition comprising said compounds, processes for their preparation and use".
UY28702A1 (en) QUINAZOLINE DERIVATIVES
DOP2016000308A (en) COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER
DOP2014000034A (en) BENZOFURAN COMPOUNDS FOR USE IN THE TREATMENT OF INFECTIONS BY HEPATITIS C VIRUS (HCV)
NI201900094A (en) DEUTERATED IMIDAZO [4, 5-c] QUINOLIN-2-ONA TYPE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
BRPI0509667B8 (en) compound, process for the preparation of a compound of formula (I), medicine and use of a compound
BR112017007953A2 (en) crystalline form of a jak kinase inhibitor bisulfate and method of preparation thereof
CU20210007A7 (en) ARIL-N-ARYL DERIVATIVES FOR THE TREATMENT OF A RIBONUCLEIC ACID (RNA) VIRUS INFECTION
EP3831839A3 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
ECSP088472A (en) DERIVATIVES OF 9-CHLORINE-15-DEOXIPROSTAGLANDIN, PROCESSES FOR ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure